Breaking Down Isoray, Inc. (ISR) Financial Health: Key Insights for Investors

Isoray, Inc. (ISR) trades at $2.54 per share (down $0.12, -0.05%) with an intraday high/low of $2.815/$2.53, volume of 2,789,779 and last trade at Tuesday, December 16, 01:15:00 UTC-yet beneath these market ticks lie stark fundamentals: annual revenue of approximately $10.80 million with quarterly sales of $2.56 million (missing $2.58M expectations) and a record Q2 2024 haul of $8.5 million (up 30% YoY) driven by Cesium-131 products that made up over 70% of revenue and contracts with 200+ hospitals; profitability, however, shows a net loss of -$7.27 million and a net margin of -115.91% with TTM EPS of -$0.07 and negative ROE/ROA (ROE -66.64%, ROA -47.51%), while the balance sheet displays very low leverage (debt/equity 0.02), exceptional liquidity (current ratio 14.38, quick ratio 13.99), market capitalization and enterprise value of $54.57 million, beta 1.36, and 142.11 million outstanding shares-read on to explore how these figures, valuation signals (P/E -2.21, P/B 1.37, EV/EBITDA 9.00), and risk factors shape ISR's investor case.

Isoray, Inc. (ISR) - Revenue Analysis

• Top-line sensitivity: At a market price of $2.54 and elevated intraday volume (2,789,779), investor attention can rapidly amplify reactions to quarterly revenue beats or misses.
• Short-term price action: Intraday range (low $2.53 - high $2.815) signals thin liquidity can cause outsized moves on relatively small news items or revenue revisions.
• Trading context: The modest reported change (-$0.12, -0.05%) versus the prior close masks intraday volatility between the open ($2.71) and the low ($2.53).

• Primary revenue streams: Procedural product sales and services tied to brachytherapy isotopes, which typically show lumpy, procedure-driven monthly receipts.
• Growth catalysts: Increased adoption of targeted brachytherapy treatments, reimbursement shifts, and new clinical partnerships or distribution agreements.
• Near-term risks: Procedure volume sensitivity to hospital capital cycles and any supply-chain disruptions for isotopes or delivery devices.

• Quarterly revenue vs. consensus: watch revisions and management commentary for procedure volumes and distributor orders.
• Order book/backlog updates: any multi-period supply agreements materially change forward visibility.
• Gross margin trends: monitor for changes driven by product mix or isotope sourcing costs.
• Cash flow from operations: given ISR's small-cap profile, operational cash generation is critical to sustaining growth investments.

Isoray, Inc. (ISR) Profitability Metrics

• Annual revenue (most recent reported): $10.80 million.
• Most recent quarterly revenue: $2.56 million (vs. analyst expectation of $2.58 million - slight miss).
• Q2 2024 record revenue: $8.5 million, up ~30% year-over-year.
• Cesium-131 products comprised >70% of Q2 2024 revenue (core growth engine).
• Commercial footprint: contracts with 200+ hospitals and clinics across the U.S.
• Strategic focus: sustained R&D investment to broaden product offerings and defend competitive position in oncology.

• Concentration risk: Cesium-131 accounts for the majority of revenue (>70% in Q2 2024), creating high single-product exposure.
• Growth runway: Record Q2 2024 ($8.5M) and 200+ institutional contracts indicate scalable adoption in target oncology niches.
• Profitability path: Healthy gross margins (~48%) offset by negative operating margin (~-12%) as ISR invests in R&D and commercialization - near-term earnings pressure with potential leverage if sales scale further.
• Analyst sensitivity: Recent quarter slightly under consensus ($2.56M vs. $2.58M) - small variance but a reminder of close market expectations.
• Strategic R&D: Continued investment is intended to diversify product mix, reduce concentration risk, and improve long-term margin profile.

Isoray, Inc. (ISR) Debt vs. Equity Structure

• Net income: -$7.27 million (negative profitability at the bottom line)
• Net margin: -115.91% (TTM)
• Operating margin: 58.23% (latest report)
• TTM EPS: -$0.07
• Return on equity (ROE): -66.64% (primary ROE measure reported)
• Trailing twelve-month (alternate) ROE flagged as negative 17.12% in some disclosures
• Return on assets (ROA): -47.51%

• A large positive operating margin (58.23%) indicates core operations are generating gross operating profitability before interest, taxes, and non‑operating expenses.
• The deep negative net margin (-115.91%) and net loss (-$7.27M) imply significant non‑operating charges, interest expense, one‑time write‑downs, or tax effects eroding operating profits.
• Negative ROE and ROA (ROE: -66.64% / -17.12% alternate; ROA: -47.51%) reflect that equity and assets are not producing positive returns-often a sign of high leverage, asset impairments, or persistent losses.
• TTM EPS of -$0.07 confirms shareholder earnings are negative on a per‑share basis.

• If operating profit is strong but net results are negative, examine interest expense and debt levels-high leverage can convert operating earnings into net losses.
• Large discrepancies between operating margin and net margin often point to material non‑operating items (e.g., impairments, financing costs). Check recent debt issuance, convertible securities, or restructuring charges in filings.
• Volatile or negative ROE/ROA suggests either recurring losses or capital structure dilution; monitor equity raises, warrants, or unusual financing that could impact per‑share metrics.

Isoray, Inc. (ISR) - Liquidity and Solvency

• Debt-to-Equity: 0.02 - indicates minimal financial leverage.
• Current Ratio: 14.38 - denotes strong short-term liquidity and coverage of current liabilities.
• Market Cap & Enterprise Value: $54.57M - market valuation parity suggests limited net debt impact on EV.
• Outstanding Shares: 142.11M - informs per-share metric calculations and dilution considerations.
• Beta: 1.36 - implies greater sensitivity to market movements.

Isoray, Inc. (ISR) - Valuation Analysis

• Current ratio: 14.38 - ample coverage of current liabilities by current assets.
• Quick ratio: 13.99 - near-equivalent to the current ratio, indicating most current assets are liquid.
• Debt-to-assets ratio: 23.2% - moderate leverage; a meaningful portion of assets is financed with debt but the company is far from overleveraged.
• Market capitalization: $54.57 million - small-cap profile affecting liquidity of equity and investor risk perception.
• Enterprise value: $54.57 million - EV approximating market cap implies low net debt (net cash position or negligible debt adjustments).
• Beta: 1.36 - higher volatility vs. the market, implying greater sensitivity to market moves.

• Liquidity cushion: Extremely high current and quick ratios suggest Isoray can meet short-term obligations comfortably and has flexibility to fund near-term operational needs or opportunistic investments.
• Capital structure: With debt-to-assets at 23.2% and EV roughly equal to market cap, the company likely carries little net debt - reducing interest-rate sensitivity but limiting leverage-driven returns.
• Valuation context: A $54.57M market cap positions ISR as a small-cap equity; valuation multiples should be compared to peers in the medical/healthcare small-cap cohort rather than large-cap benchmarks.
• Risk profile: Beta of 1.36 signals that share price is more volatile than the market - useful for portfolio allocation and required return estimates in discounted cash flow or CAPM-based valuations.
• Analytical focus areas: Cash burn trends, capex and R&D trajectory, receivables/payables management, and any contingent liabilities that could materially change net debt and EV.

Isoray, Inc. (ISR) - Risk Factors

• Disparity between modeled intrinsic/fair values (negative) and market price indicates model stress or accounting/forecast issues - intrinsic value of -$178.95 vs. price $0.38 is an extreme divergence.
• Negative P/E (-2.21) arises from negative earnings; while sometimes read as potential undervaluation, it primarily signals loss-making operations or one-time impairments that distort simple P/E interpretation.
• P/B of 1.37 suggests equity is trading modestly above book value; investors should inspect intangible assets, goodwill, and asset write-down history to validate book value quality.
• EV/EBITDA at 9.00 is low-to-moderate and may imply attractive operating valuation, but EBITDA adjustments and nonrecurring items must be reviewed to avoid misleading conclusions.

• Financial model inconsistency: Large negative intrinsic/fair values imply models or inputs (growth, margins, discount rate) produce nonstandard outputs-risk of model fragility.
• Operating losses and earnings volatility: Negative P/E driven by negative net income increases uncertainty about near-term profitability and capital needs.
• Small market capitalization ($54.57M): Higher liquidity risk, wider spreads, and greater vulnerability to single-event impacts or dilution.
• Balance sheet quality: With P/B ~1.37, review asset composition (intangibles, inventory, receivables) and potential impairments that could change book value materially.
• Reliance on EBITDA metrics: EV/EBITDA = 9.00 looks attractive only if EBITDA is sustainable and not inflated by one-time gains or aggressive accounting.
• Regulatory and clinical risk: As a medical device/therapy-related company, clinical outcomes, FDA/health authority decisions, and reimbursement dynamics materially affect revenue trajectories.
• Capital raising/dilution risk: Loss-making status may force equity or debt raises, diluting existing shareholders or increasing leverage.
• Market perception vs. model outputs: When market price ($0.38) diverges strongly from model-derived negative values, it may reflect market optimism on catalysts not captured in conservative forecasts-or signal model misspecification.

Isoray, Inc. (ISR) - Growth Opportunities

Investors evaluating Isoray, Inc. (ISR) must weigh potential growth vectors against pronounced financial risks. Below is a focused breakdown of the company's primary risk factors and key financial metrics that influence growth potential and valuation.

Risk Factors

• Net losses: trailing net income stands at -$7.27 million, signaling ongoing profitability challenges that can constrain reinvestment and shareholder returns.
• Profitability metrics: a negative net margin of 115.91% and a trailing twelve‑month return on equity (ROE) of -17.12% reflect severely negative operating economics relative to sales and equity.
• Leverage: a debt-to-assets ratio of 23.2% indicates moderate leverage that could amplify downside risk during revenue shortfalls.
• Market sensitivity: beta of 1.36 implies higher volatility versus the overall market, increasing equity risk for investors.
• Market size and valuation: market capitalization is $54.57 million with an enterprise value reported at $54.57 million, suggesting limited market liquidity and a compact valuation base relative to peers.

Key Financial Snapshot

Investor Considerations

• Assess cash runway and financing needs given continued losses; potential dilution risk if equity raises are required.
• Monitor margin recovery catalysts - product mix improvements, cost controls, or pricing power are essential to shift negative margins toward breakeven and positive ROE.
• Consider the implications of moderate leverage: manageable today but potentially restrictive if growth requires capital expenditure or working capital increases.
• Be prepared for elevated share-price volatility (beta 1.36) and limited liquidity given modest market cap and EV figures.
• Cross-reference company history, strategy and ownership structure for alignment with growth plans: Isoray, Inc. (ISR): History, Ownership, Mission, How It Works & Makes Money